COMP <GO>
TARS vs ABBV // NET PROFIT MARGIN
Tarsus Pharmaceuticals Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: TARS 2
— ABBV 8
▲ NET PROFIT MARGIN LEADER: ABBV
LAST: $74.20 (+2.98%) • MKT CAP: $3.66B
net-margins
-14.60%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
net-margins
6.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TARS VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TARS | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 70.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -24.10% | 29.00% | -53.10 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.61% | 3.47% | -4.08 | ABBV | /fcf-yield <GO> |
| Operating Margin | -15.70% | 24.60% | -40.30 | ABBV | /operating-margins <GO> |
| Net Profit Margin ACTIVE | -14.60% | 6.90% | -21.50 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 146.70% | 8.60% | +138.10 | TARS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 10.19 | 5.33 | +4.86 | TARS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.1 | 65.1 | -9.99 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.66B | $513.86B | -$510.20B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TARS REV | ABBV REV | TARS GROSS % | ABBV GROSS % | TARS FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $451.4M | $61.16B | — | 70.2% | -$22.3M | $17.82B |
| FY 2024 | $183.0M | $56.33B | — | 70.0% | -$84.6M | $17.83B |
| FY 2023 | $17.4M | $54.32B | — | — | -$117.5M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TARS // BETA —
ABBV // BETA 1.15